Login to Your Account



Lilly's diabetes drug give-back tumbles Transition shares

By Michael Fitzhugh
Staff Writer

Monday, April 18, 2016

Eli Lilly and Co. is returning rights for a phase II diabetes drug for which it paid $7 million to Transition Therapeutics Inc., after deciding against carrying the candidate into phase III development.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription